Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 281-288

  Campbell, Derna ^a,b,d   Thomson, Alison H ^a,b,c   Stack, Bryan ^a  

^a GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Aminoglycoside antibiotics; Cystic fibrosis; Population pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CREATININE; GENTAMICIN; TOBRAMYCIN;

ADOLESCENT; ADULT; ARTICLE; BODY SURFACE; COMPARTMENT MODEL; CREATININE BLOOD LEVEL; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LINEAR MODELS; MALE; METABOLIC CLEARANCE RATE; POPULATION SURVEILLANCE;

EID: 0033003973     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00004     Document Type: Article

References (24)

1. Levy J, Smith AL, Koup JR, Williams-Warren J, Ramsey B. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr 1984;105:117-24.
2. Groot R, Smith A. Antibiotic pharmacokinetics in cystic fibrosis patients. Clin Pharmacokinel 1987;13:228-53.
3. Touw DJ, Vinks AATMM, Mouton JW, Horrevorts AM. Pharmacokinetic optimisation of antibacterial treatment in patients with cystic fibrosis. Clin Pharmacokinet 1998;35:437-59.
4. Kelman AW, Whiting B, Bryson SM. OPT: a package of computer programs for parameter estimation in clinical pharmacokinetics Br J Clin Pharmacol 1982;14:247-56.
5. Cockcroft DW, Gault H. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
6. Traub SL, Johnson CE. Comparison of methods estimating creatinine clearance in children. Am J Hosp Pharm 1980;37:195-200.
7. Devine JB. Gentamicin therapy. Drug Intell Clin Pharm 1974;8: 650-5.
8. DuBois D, DuBois EF. A formula to estimate appropriate surface area if height and weight are known. Arch Intern Med 1916;17: 263-71
9. Hallynck TH, Soep HH, Thomis JA, Boelaert J, Daneels R, Dettli L. Should clearance be normalised to body surface area or to lean body mass? Br J Clin Pharmacol 1981;11:523-5.
10. NONMEM Users Guides 1992. Beal SL, Sheiner LB (eds). NON-MEM Project Group, University of California at San Francisco, San Francisco.
11. Watling SM, Dasta JF. Aminoglycoside dosing considerations in intensive care patients. Ann Pharmacother 1993;27:351-7.
12. Tholl DA, Shikuma LR, Miller TQ, Woodward JM, Cerra FB, Zaske DE. Physiologic response of stress and aminoglycoside clearance in critically ill patients. Crit Care Med 1993;21:248-51.
13. Kildoo CW, Harralson AF, Folli HL, Kelly PC. Direct determination of tobramycin clearance in patients with mild-moderate cystic fibrosis. Drug Intell Clin Pharm 1987;21:639-41.
14. Bauer LA, Piecoro Jr JJ, Wilson HD, Blouin RA. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis. Clin Pharm 1983;2:262-4.
15. Horrevorts A.M, Degener JE, Dzoljic-Danilovic G, Michel MF, Kerrebijn KF. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Chest 1985;88:260-4.
16. Kelly KW, Menendez R, Fan L, Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr 1982;100:318-21.
17. Delange G, Desautels L, Legault S, et al. Individualized aminoglycoside dosage regimens in patients with cystic fibrosis. Drug Intell Clin Pharm 1988;22:386-9.
18. Hsu M-C, Aguila H, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G. Individualization of trobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis J 1984;3:526-9.
19. Touw DJ, Vinks AATMM, Heijerman HGM, Hermans J, Bakker W. Suggestions for optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1994;16:125-31.
20. Touw DJ, Vinks AATMM, Jacobs F, Heijerman HGM, Bakker W. Creatinine clearance as a predictor of tobramycin elimination in adults with cystic fibrosis. Ther Drug Monit 1996;18:562-69.
21. Rosario M, Thomson AH, Jodrell D, Elliott HL. Population pharmacokinetics of gentamicin in patients with cancer. Br J Clin Pharmacol 1998;46:229-36.
22. Matzke GR, Millikin SP, Kovarik JM. Variability in pharmacokinetic values for gentamicin, tobramycin and netilmicin in patients with renal insufficiency. Clin Pharm 1989;8:800-6.
23. Assael BM, Cavanna G, Jusko WJ, et al. Multiexponential elimination of gentamicin. A kinetic study during development. Dev Pharmacol Ther 1980;1:171-81.
24. Thomson AH, Duncan N, Silverstein B, Alcock S, Jodrell D. Development of guidelines for gentamicin dosing. J Antimicrob Chemother 1996;38:885-93.